8-K: iSpecimen Faces Nasdaq Delisting Risk, Gets Extension

iSpecimen Inc. has received an extension until November 25, 2026, to regain compliance with Nasdaq's minimum stockholders equity requirement, facing potential delisting if compliance is not demonstrated.

Summary

• iSpecimen Inc. received a deficiency letter from Nasdaq on September 8, 2026, regarding failure to meet Listing Rule 5550(b).
• This rule requires a minimum of $2,500,000 in stockholders equity, $35,000,000 in market value of listed securities, or $500,000 in net income.
• The company was previously notified of non-compliance on May 29, 2026.
• iSpecimen has submitted compliance plans, including a private placement of $2.5 million and a planned $5 million public offering.
• Financial projections indicate stockholders equity of approximately $5.1 million through June 30, 2027.
• Nasdaq has granted an extension until November 25, 2026, for the company to evidence compliance.
• Failure to comply by this date, or in the next periodic report, could lead to delisting.
• The deficiency letter does not immediately affect the trading of iSpecimen's common stock.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to the continued risk of delisting from Nasdaq, despite an extension.

Positives

• Nasdaq has granted an extension until November 25, 2026, to regain compliance with listing rules.
• A private placement closed on May 11, 2026, generating approximately $2.5 million in gross proceeds.
• The company plans a best-efforts public offering to raise approximately $5 million in gross proceeds.
• Financial projections suggest stockholders equity of approximately $5.1 million through June 30, 2027, which would meet the requirement.
• The deficiency letter has no immediate effect on the listing or trading of the company's common stock.

Negatives

• The company received a deficiency letter from Nasdaq for failing to meet Listing Rule 5550(b) regarding minimum stockholders equity.
• The company was previously notified of non-compliance on May 29, 2026.
• There is a risk of delisting if the company fails to evidence compliance by November 25, 2026, or in its next periodic report.
• There can be no assurance that the company will be able to regain or maintain compliance.

Risks

• The risk that the company may not regain compliance with Nasdaq Listing Rule 5550(b) within the extension period.
• The risk that the planned public offering may not be completed on the expected terms or timeline, or at all.
• The risk that any transaction or event may not be sufficient to enable the company to satisfy the stockholders equity requirement.
• The risk that, even if compliance is regained, the company may not maintain compliance.
• The risk of delisting if the company fails to evidence compliance in its next periodic report.
• Other risks and uncertainties described in the company's SEC filings.

Future Outlook

The company intends to regain compliance with Nasdaq Listing Rule 5550(b) by the November 25, 2026 deadline through various actions, including a planned public offering. However, there is no assurance of success, and failure to comply could result in delisting.

Management Comments

• The Company intends to regain compliance with the Rule within the extension period and is evaluating available alternatives to satisfy the requirements.
• There can be no assurance that the Company will be able to regain compliance or maintain compliance.
• If the Company does not satisfy the terms of the extension, Nasdaq Staff will provide written notification that the Company's securities will be delisted, at which time the Company may appeal Staff's determination to a Hearings Panel.

Industry Context

StockSavvy.ai notes that Nasdaq's listing rules are designed to ensure a minimum level of financial health and market capitalization for listed companies. Companies facing delisting often undertake capital raises or strategic initiatives to meet these requirements. The success of iSpecimen's planned public offering will be critical.

Stakeholder Impact

• Shareholders: Continued uncertainty regarding the company's listing status on Nasdaq could negatively impact share price and investor confidence. Successful capital raises and compliance would be positive.
• Creditors: The company's ability to meet financial obligations may be indirectly affected by its listing status and access to capital.
• Employees: Potential delisting could create job insecurity and affect morale.
• Nasdaq: The exchange is monitoring the company's adherence to its listing standards.

Next Steps

• The company must evidence compliance with Nasdaq Listing Rule 5550(b) by November 25, 2026.
• The company will choose one of two alternatives to report compliance to the SEC and Nasdaq.
• The company may be subject to delisting if its next periodic report does not evidence compliance.
• If the company fails to satisfy the terms of the extension, Nasdaq Staff will provide written notification of delisting, with an option to appeal.

Key Dates

Recommendation

The company is in a precarious position regarding Nasdaq compliance, with a clear risk of delisting. While there are plans for capital raises and projected improvements in equity, the outcome is uncertain. A 'hold' recommendation reflects the significant risk alongside potential upside if compliance is achieved, warranting close monitoring rather than immediate action.

Keywords

Nasdaq compliance, Stockholders equity, Delisting risk, Public offering, Listing rule, Financial projections, Capital raise